Boston Scientific will purchase Ajax Health's Cortex and its OptiMap system to guide physicians performing AFib-treating ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

This growth is primarily driven by the rising prevalence of cardiovascular diseases (CVDs) worldwide, alongside continuous ...

Massachusetts-based Boston Scientific generates most of its revenue from sales of its heart devices, such as pacemakers and stents. It also makes equipment to diagnose and treat a range of ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

(Reuters) -Boston Scientific increased its annual profit forecast on Wednesday, fueled by strong demand for its cardiac implants, but temporarily halted a pivotal heart equipment study citing ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

The Cardiac Rhythm Management (CRM ... around $4bn in 2023 and is forecast to reach around $5.8bn by 2033. Boston Scientific’s Farapulse PFA system gained a CE mark in Europe in 2021 and ...

Boston Scientific has signed a definitive agreement for the acquisition of an Ajax Health company, Cortex, to bolster its ...

(Reuters) - Boston Scientific raised its annual profit forecast and exceeded Wall Street's estimates for third-quarter profit on Wednesday, driven by robust demand for its heart devices ...